A team of researchers from the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru and the BRIC-National Institute of Biomedical Genomics (NIBMG), Kalyani, in collaboration with clinicians from Sri Devraj Urs Academy of Higher Education and Research (SDUAHER), Kol
Gurugram (Haryana) [India], August 8: Gurugram-based Dr. Gitanjali Ramchandani and Siddhant Minocha have developed a new AI technology designed to detect chronic diseases years in advance. Their platform, Purna AI, identifies over 75 clinical and sub-clinical patterns using blood biomarkers,
An international team of researchers has identified a potential microbial culprit behind the alarming rise in early-onset colorectal cancer: a bacterial toxin called colibactin.
To get to the bottom of this, the National Institute of Mental Health (NIMH) initiated a consortium called SSPsyGene (sspsygene.ucsc.edu) in 2023, uniting research teams from renowned US universities with the joint goal of characterising the genetic origins of NPD, focusing on 250 selected h
A new study discovered that the SMCHD1 protein controls how genes are digested, which influences the course of Facioscapulohumeral Muscular Dystrophy (FSHD). This finding about SMCHD1's role in gene regulation is significant because it opens new avenues for creating tailored therapeutic tech
GHRD, which is defined by the body's inability to use its growth hormone and leads to stunted development, has been linked in mice to a 40 per cent increase in longevity and decreased risk of numerous age-related disorders. However, the risk of cardiovascular illness in individuals with GHRD
A recent joint investigation identified uncommon mutations in the YKT6 gene as the source of a novel neurological illness characterised by developmental delays, severe progressive liver disease, and a risk of liver cancer.
Ahmedabad (Gujarat) [India], March 14: In a significant stride towards making advanced cancer treatment accessible to all, Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers
A U.S.-Canadian study collaboration led by Vanderbilt University Medical Center found common, age-related blood changes as a risk factor for acute kidney injury (AKI), which affects more than one in every five hospitalized persons worldwide.
Every cell produces its own proteins by utilising the genetic information contained in its genes. Mutations are changes in this information that can disrupt the function of the affected proteins. This is known as cancer genetics in oncology. However, in recent decades, a new area has emerged
For far too long, cancer treatment has been a double-edged sword, with treatments designed to target cancer cells sometimes harming healthy cells as well.
For far too long, cancer treatment has been a two-edged sword, with therapies designed to target cancer cells frequently wreaking damage on good cells as well.